Dutch Health Budget "Unrealistic"

28 July 1996

The Dutch government's declared intention of keeping annual health care spending growth to no more than 1.3% is unrealistic, given low interest rates and the exchange rate of the guilder against the US dollar, says the Nederlandse Zorgfederatie, the federation of hospitals, psychiatric institutions, nursing homes and homes for the handicapped.

D66, the Social Democrat-tending political party which forms one-third of the government ministers' council, has called for more money for health care, but the other two parties, the VVD (Liberals) and the PvdA (Social Democrats) rejected its proposal for an annual increase in health spending of 1.8%. Health Minister Els Borst is a member of D66.

Copayment Changes Meantime, the Cabinet proposes that from January 1, all fund members should pay 20% of their health care costs, up to a maximum of 200 guilders ($120), with those on low incomes required to pay up to 100 guilders. However, the Sickfund Council has warned of the difficulties of implementing this proposal, because of differences in declaration methods and the many agreements in existence between insurers, hospitals and fund members.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight